BMP15

Across TCGA pan-cancer cohorts, BMP15 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BMP15 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher BMP15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BMP15 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

CHOL, DLBC, and CESC are the cancer types where BMP15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.545	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BMP15–CHOL (OS)

Open the CHOL breakdown →